TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29415668

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 44

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 44
Study: 26742001

Group type: EXPERIMENTAL
Intervention: Live Attenuated Influenza Vaccine (LAIV), administered to 77 children, analyzed 63 children after vaccination.
Number of subjects: 151

Group type: COMPARATOR
Intervention: Control group (non-recipients of LAIV), 74 children, analyzed 72 children.
Number of subjects: 151
Study: 24771132

Group type: EXPERIMENTAL
Intervention: Cooling vest
Number of subjects: 10
Study: 21985488

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (800 mg/day, intravenous infusion and oral supplementation)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (no pentoxifylline)
Number of subjects: 96
Study: 19671203

Group type: EXPERIMENTAL
Intervention: Capsinoids (1 mg)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Capsinoids (3 mg)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Capsinoids (6 mg)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Capsinoids (12 mg)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 19046245

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 824
Study: 15838406

Group type: COMPARATOR
Intervention: Medical care only (MD)
Number of subjects: 681

Group type: EXPERIMENTAL
Intervention: Chiropractic care only (DC)
Number of subjects: 681

Group type: EXPERIMENTAL
Intervention: Chiropractic care with physical modalities (DCPm)
Number of subjects: 681

Group type: EXPERIMENTAL
Intervention: Medical care with physical therapy (MDPt)
Number of subjects: 681
Study: 11461054

Group type: EXPERIMENTAL
Intervention: Computer-simulated point-light demonstrations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Normal video demonstrations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Real-time demonstrations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Slow-motion demonstrations
Number of subjects: 0
Study: 9609609

Group type: EXPERIMENTAL
Intervention: Intravenous aminophylline therapy
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo (0.9% saline solution)
Number of subjects: 38
Study: 7925877

Group type: EXPERIMENTAL
Intervention: Candoxatril 200 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 3354350

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 1306679

Group type: EXPERIMENTAL
Intervention: Triclosan/copolymer dentifrice (0.3% triclosan and 2.0% copolymer)
Number of subjects: 325

Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 325
Study: 417428

Group type: EXPERIMENTAL
Intervention: Hydergine (Sandoz)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Mannitol
Number of subjects: 300

Group type: COMPARATOR
Intervention: General supportive treatment
Number of subjects: 300
Study: 31147306

Group type: EXPERIMENTAL
Intervention: Intra-aortic balloon pump (IABP) 50 mL
Number of subjects: 32

Group type: COMPARATOR
Intervention: Inotropes (INO: enoximone or dobutamine)
Number of subjects: 32
Study: 27832835

Group type: EXPERIMENTAL
Intervention: Rescue antenatal steroids
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study: 26459347

Group type: EXPERIMENTAL
Intervention: Combined epidural-general anesthesia plus postoperative epidural analgesia
Number of subjects: 1800

Group type: COMPARATOR
Intervention: General anesthesia plus postoperative intravenous analgesia
Number of subjects: 1800
Study: 24267010

Group type: EXPERIMENTAL
Intervention: CNV1014802
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 21212157

Group type: EXPERIMENTAL
Intervention: 250 mg BIBF 1120 b.i.d.
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: 150 mg BIBF 1120 b.i.d.
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: BIBF 1120 (both doses)
Number of subjects: 73
Study: 19364975

Group type: EXPERIMENTAL
Intervention: Alert from hospital staff to attending physician
Number of subjects: 2493

Group type: COMPARATOR
Intervention: No alert issued (Control)
Number of subjects: 2493
Study: 17374147

Group type: EXPERIMENTAL
Intervention: AKL1
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 15153206

Group type: EXPERIMENTAL
Intervention: Double-breath (DB) VC inhalation induction with 8% sevoflurane in 66% nitrous oxide
Number of subjects: 104

Group type: COMPARATOR
Intervention: Single-breath (SB) VC inhalation induction with 8% sevoflurane in 66% nitrous oxide
Number of subjects: 104
Study: 11409130

Group type: EXPERIMENTAL
Intervention: Glucosamine sulfate (GS) 500 mg tid
Number of subjects: 39

Group type: COMPARATOR
Intervention: Ibuprofen 400 mg tid
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Glucosamine sulfate (GS)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 39
Study: 9773910

Group type: EXPERIMENTAL
Intervention: Oral prednisone (2 mg/kg/day) for 3 days
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo for 3 days
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Both groups (prednisone and placebo)
Number of subjects: 38
Study: 8153771

Group type: EXPERIMENTAL
Intervention: Cefotaxime 500 mg
Number of subjects: 222

Group type: COMPARATOR
Intervention: Ceftriaxone 250 mg
Number of subjects: 222
Study: 3079005

Group type: EXPERIMENTAL
Intervention: Defibrotide (400 mg twice daily, administered intramuscularly)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Calcium heparin (5,000 IU thrice daily, administered subcutaneously)
Number of subjects: 63

Group type: COMPARATOR
Intervention: ASA (100 mg on alternate days, administered orally)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Defibrotide
Number of subjects: 63

Group type: COMPARATOR
Intervention: Calcium heparin
Number of subjects: 63

Group type: COMPARATOR
Intervention: ASA
Number of subjects: 63
Study: 31899878

Group type: EXPERIMENTAL
Intervention: Subcutaneous sumatriptan administration
Number of subjects: 60

Group type: COMPARATOR
Intervention: No sumatriptan administration (Control)
Number of subjects: 60
Study: 31166599

Group type: EXPERIMENTAL
Intervention: Alirocumab 300 mg Q4W
Number of subjects: 458

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 458
Study: 28637470

Group type: EXPERIMENTAL
Intervention: Girls in Sport intervention
Number of subjects: 1769

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1769
Study: 25733626

Group type: EXPERIMENTAL
Intervention: Plant sterols (PS) consumption (2 g PS/d for 28 days)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Plant sterols (PS) consumption (2 g PS/d for 28 days) in LS individuals
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Plant sterols (PS) consumption (2 g PS/d for 28 days) in HS individuals
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Plant sterols (PS) consumption (2 g PS/d for 28 days) in LS participants
Number of subjects: 63
Study: 23256446

Group type: EXPERIMENTAL
Intervention: 12‐week honey consumption (0.5 mL/kg body weight per day)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Long-term effects after honey withdrawal
Number of subjects: 20
Study: 21530103

Group type: EXPERIMENTAL
Intervention: Swanson implants
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: NeuFlex implants
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Overall patient motivations for surgery
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Overall patient satisfaction
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Michigan Hand Questionnaire
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Sollerman hand function test
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Range of motion, ulnar drift, grip strength
Number of subjects: 33
Study: 18316155

Group type: EXPERIMENTAL
Intervention: Atosiban i.v.
Number of subjects: 140

Group type: COMPARATOR
Intervention: Ritodrine i.v.
Number of subjects: 140
Study: 16493482

Group type: EXPERIMENTAL
Intervention: Otamixaban (0.3 mg/kg)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Otamixaban (0.5 mg/kg)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Otamixaban (0.3 mg/kg) with ASA (300 mg once a day)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Otamixaban (0.5 mg/kg) with ASA (300 mg once a day)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) (300 mg once a day)
Number of subjects: 68
Study: 12859127

Group type: EXPERIMENTAL
Intervention: Indirect word learning
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Direct word learning
Number of subjects: 96
Study: 11168746

Group type: EXPERIMENTAL
Intervention: Curette/curette
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Curette/teflon‐coated sonic scaler
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Teflon‐coated sonic scaler/teflon‐coated sonic scaler
Number of subjects: 10

Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 10
Study: 9783766

Group type: EXPERIMENTAL
Intervention: Penicillamine
Number of subjects: 541

Group type: EXPERIMENTAL
Intervention: Sodium aurothiomalate
Number of subjects: 541

Group type: EXPERIMENTAL
Intervention: Auranofin
Number of subjects: 541

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Number of subjects: 541

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 541
Study: 7843470

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 48

Group type: COMPARATOR
Intervention: Glipizide
Number of subjects: 48
Study: 2455840

Group type: EXPERIMENTAL
Intervention: Xamoterol, 200 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Prenalterol, 50 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Salbutamol, 8 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: ICI 118,551, 25 mg with Xamoterol
Number of subjects: 8

Group type: COMPARATOR
Intervention: ICI 118,551, 25 mg with Prenalterol
Number of subjects: 8

Group type: COMPARATOR
Intervention: ICI 118,551, 25 mg with Salbutamol
Number of subjects: 8
Study: 31533552

Group type: EXPERIMENTAL
Intervention: Pharmacogenomics testing using OneOme RightMed comprehensive test
Number of subjects: 155
Study: 29170309

Group type: EXPERIMENTAL
Intervention: New prognostic model for management of blunt chest wall trauma patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal care (control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SF-12v2 and Client Services Receipt Inventory surveys
Number of subjects: 0
Study: 25514106

Group type: EXPERIMENTAL
Intervention: Denosumab, 60 mg s.c. every 6 months
Number of subjects: 1703

Group type: COMPARATOR
Intervention: Oral bisphosphonates (ibandronate or risedronate, 150 mg once monthly for 12 months)
Number of subjects: 1703
Study: 23466048

Group type: EXPERIMENTAL
Intervention: DASH diet
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 32
Study: 21533723

Group type: EXPERIMENTAL
Intervention: frovatriptan 2.5 mg
Number of subjects: 76

Group type: COMPARATOR
Intervention: zolmitriptan 2.5 mg
Number of subjects: 76
Study: 19167726

Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 941

Group type: EXPERIMENTAL
Intervention: Nedocromil
Number of subjects: 941

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 941
Study: 16730606

Group type: EXPERIMENTAL
Intervention: Adolescent Patient-Provider Interaction Scale (APPIS)
Number of subjects: 192
Study: 15259834

Group type: EXPERIMENTAL
Intervention: Citalopram, 20 mg/day
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 11423808

Group type: EXPERIMENTAL
Intervention: Protective head and shoulder equipment (pads group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No protective equipment (no pads group)
Number of subjects: 20
Study: 9125637

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg capsule with water
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Omeprazole granules with orange juice
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Omeprazole granules with Alka-Seltzer solution
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Omeprazole granules with apple sauce
Number of subjects: 11
Study: 8238221

Group type: EXPERIMENTAL
Intervention: Carteolol 1.0% (one drop twice daily in both eyes)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Timolol 0.5% (one drop twice daily in both eyes)
Number of subjects: 58
Study: 3517284

Group type: EXPERIMENTAL
Intervention: Cholestyramine (4 g/d)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Phenobarbital (7.5 to 10 mg/kg/d)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 80
Study: 31910669

Group type: EXPERIMENTAL
Intervention: Dynamic CT-MPI+CCTA-guided strategy
Number of subjects: 240

Group type: COMPARATOR
Intervention: CCTA-guided strategy
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 240
Study: 30425469

Group type: COMPARATOR
Intervention: CHF6001 (20, 100, 200, 400, 800, 1,600, and 2,000 µg) via SDDPI
Number of subjects: 2

Group type: COMPARATOR
Intervention: CHF6001 (2,400, 4,000, and 4,800 µg) via MDDPI
Number of subjects: 2

Group type: COMPARATOR
Intervention: CHF6001 (100, 300, 600, 1,200, and 1,600 µg) once daily via SDDPI
Number of subjects: 2

Group type: COMPARATOR
Intervention: CHF6001 (1,200, 2,000, or 2,400 µg) twice daily via MDDPI
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: CHF6001
Number of subjects: 2
Study: 27448534

Group type: EXPERIMENTAL
Intervention: Higher loop diuretic doses during hospitalization
Number of subjects: 121
Study: 24695771

Group type: EXPERIMENTAL
Intervention: Nutrition education intervention (1 face-to-face session, 2 follow-up calls, 3 pamphlets)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Usual care (handouts with guidelines on healthy eating)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Nutrition education intervention
Number of subjects: 56
Study: 22529085

Group type: EXPERIMENTAL
Intervention: Mobile-bearing prostheses
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Fixed-bearing prostheses
Number of subjects: 55
Study: 20456831

Group type: EXPERIMENTAL
Intervention: Sub-maximal exercise (cycling at 70% VO(2max) intensity until exhaustion)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-exercise trial (seated for the duration of the experiment)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sub-maximal exercise
Number of subjects: 0
Study: 17852636

Group type: EXPERIMENTAL
Intervention: Methotrexate (15 mg) + Betamethasone (3 mg) weekly
Number of subjects: 40

Group type: COMPARATOR
Intervention: Methotrexate (15 mg) weekly
Number of subjects: 40
Study: 16051542

Group type: EXPERIMENTAL
Intervention: Qi-therapy (external Qigong) for four weeks
Number of subjects: 43

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Qi-therapy (external Qigong)
Number of subjects: 43
Study: 12030598

Group type: EXPERIMENTAL
Intervention: ADHD children
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study: 10024861

Group type: EXPERIMENTAL
Intervention: Staples, close immediately
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Staples, close after protamine administration
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Subcuticular sutures, close immediately
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Subcuticular sutures, close after protamine
Number of subjects: 77
Study: 11563407

Group type: EXPERIMENTAL
Intervention: 10 mg oral fosinopril
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 7.5 mg IV fosinoprilat
Number of subjects: 12

Group type: COMPARATOR
Intervention: Comparison to Western control group
Number of subjects: 12
Study: 1854169

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (200 to 300 mg every 12 h)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Piperacillin plus amikacin
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 101
Study: 6364886

Group type: EXPERIMENTAL
Intervention: Mesterolone (75 mg/day)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Testicular biopsy score
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Mesterolone
Number of subjects: 59
Study: 31521646

Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 24354

Group type: COMPARATOR
Intervention: Non-smokers (control group)
Number of subjects: 24354

Group type: EXPERIMENTAL
Intervention: Smoking status (as a predictor)
Number of subjects: 24354
Study: 30593267

Group type: EXPERIMENTAL
Intervention: High-Carbohydrate (HC) meal
Number of subjects: 46

Group type: COMPARATOR
Intervention: Normo-Carbohydrate (NC) meal
Number of subjects: 46

Group type: COMPARATOR
Intervention: High-Fat (HF) meal
Number of subjects: 46
Study: 26147898

Group type: EXPERIMENTAL
Intervention: Ethanol at BAC of approximately 0.5 g/L
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ethanol at BAC of approximately 0.9 g/L
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sober condition (0 g/L BAC)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Simulator driving with ethanol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Test track driving with ethanol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Standard deviation of lateral position (SDLP)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Other driving-related measures
Number of subjects: 20
Study: 23929664

Group type: EXPERIMENTAL
Intervention: Telehealth problem-solving therapy (tele-PST)
Number of subjects: 42
Study: 22819521

Group type: COMPARATOR
Intervention: Budesonide 800 μg/d
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Budesonide 400 μg/d plus montelukast 10 mg/d
Number of subjects: 26
Study: 20119873

Group type: EXPERIMENTAL
Intervention: Referenced decision aid
Number of subjects: 108

Group type: COMPARATOR
Intervention: Anonymous pulmonologist
Number of subjects: 108
Study: 17894791

Group type: EXPERIMENTAL
Intervention: Augmented transfusion strategy (transfusion of 2 units of RBCs when Hb < 120 g/L)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard transfusion strategy (transfusion of 2 units of RBCs when Hb < 80 g/L)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Control and experimental groups
Number of subjects: 60
Study: 16145532

Group type: EXPERIMENTAL
Intervention: Reconstruction of the iliac crest with commercially available tricalcium phosphate bone void filler
Number of subjects: 30

Group type: COMPARATOR
Intervention: No graft site reconstruction
Number of subjects: 30
Study: 12032650

Group type: EXPERIMENTAL
Intervention: Fish advice
Number of subjects: 1030

Group type: EXPERIMENTAL
Intervention: Fat and fibre advice
Number of subjects: 1030

Group type: EXPERIMENTAL
Intervention: Fat advice
Number of subjects: 1030
Study: 10486649

Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy
Number of subjects: 25

Group type: COMPARATOR
Intervention: No estrogen replacement therapy (Control)
Number of subjects: 25
Study: 8564101

Group type: EXPERIMENTAL
Intervention: Terbutaline 7.5 mg twice a day for 2 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Budesonide 400 micrograms twice a day by inhalation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Prednisolone 40 mg orally 12 h before second examination
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo orally 12 h before second examination
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Terbutaline treatment
Number of subjects: 30
Study: 1920340

Group type: EXPERIMENTAL
Intervention: Captopril (25 mg twice daily)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Nifedipine AR (20 mg twice daily)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo (1 tab twice daily)
Number of subjects: 27
Study: 7045292

Group type: EXPERIMENTAL
Intervention: Disopyramide
Number of subjects: 10

Group type: COMPARATOR
Intervention: Procainamide
Number of subjects: 10
Study: 31792485

Group type: EXPERIMENTAL
Intervention: Combined orthodontic treatment and conventional periodontal splint (experimental group)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional periodontal splint (control group)
Number of subjects: 50
Study: 29065885

Group type: EXPERIMENTAL
Intervention: Higher serum bilirubin concentrations (measured prior to first AECOPD) in the STATCOPE study (n=853)
Number of subjects: 1871

Group type: EXPERIMENTAL
Intervention: Higher serum bilirubin concentrations (measured prior to first AECOPD) in the MACRO study (n=1018)
Number of subjects: 1871
Study: 24965797

Group type: EXPERIMENTAL
Intervention: Trauma-focused cognitive behavioral therapy (TF-CBT)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Eye movement desensitization and reprocessing (EMDR)
Number of subjects: 48
Study: 23364500

Group type: EXPERIMENTAL
Intervention: Poor nutritional status (measured by Mini Nutritional Assessment - MNA)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Urinary tract infection (UTI)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Cognitive status (measured by Mini Mental State Examination - MMSE)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Dependence in feeding
Number of subjects: 188
Study: 21978518

Group type: EXPERIMENTAL
Intervention: Total disc replacement (TDR)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Fusion
Number of subjects: 152
Study: 19852337

Group type: EXPERIMENTAL
Intervention: Elective re-siting of intravenous cannulae every 48 hours
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group with cannulae removed only if painful, dislodged, or showing signs of PVT
Number of subjects: 42
Study: 17572322

Group type: EXPERIMENTAL
Intervention: 1-minute group (2 L/min oxygen and 4 L/min nitrous oxide for 1 minute)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: 2-minute group (2 L/min oxygen and 4 L/min nitrous oxide for 2 minutes)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: 3-minute group (2 L/min oxygen and 4 L/min nitrous oxide for 3 minutes)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: 5-minute group (2 L/min oxygen and 4 L/min nitrous oxide for 5 minutes)
Number of subjects: 53
Study: 15635511

Group type: EXPERIMENTAL
Intervention: Median nerve response (group 1)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Musculocutaneous nerve response (group 2)
Number of subjects: 130
Study: 12199264

Group type: EXPERIMENTAL
Intervention: Gabapentin (1,800 to 3,600 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 0